> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA OKs Rezglovar Insulin Glargine Biosimilar
- URL: https://www.fdaweb.com/fda-oks-rezglovar-insulin-glargine-biosimilar/
- Published: 2022-01-03T12:00:00.000Z
- Updated: 2026-09-14T17:26:40.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5150833

FDA has approved Lilly’s Rezglovar (insulin glargine-aglr), a second approved biosimilar to Sanofi’s insulin glargine, indicated to improve glycemic response in children and adults with Type 1 diabetes and adults with Type 2 diabetes. Lilly [says](https://www.healio.com/news/endocrinology/20211223/fda-approves-second-insulin-glargine-biosimilar?ref=fdaweb.com) Rezglovar is available as a 3 ml prefilled KwikPen to be administered once daily.

The agency approved Semglee’s Vitaris (insulin glargine-yfgn) 7/2021.